Laboratoire Tilman has acquired Promogen
The shareholders of Promogen have sold the company to Laboratoire Tilman.
Founded in 1956, Laboratoire Tilman is a Belgium pharmaceutical laboratory specialized in the development, production and marketing of phytotherapy products and is the leader in the field of medicinal plants in Belgium. The company offers a range of more than 100 natural herbal solutions sold in over 30 countries, including best-selling products such as Flexofytol, Sedistress and Antimetil.
Founded in 2012, Promogen is an external independent French pharmaceutical network that promotes, sells and distributes a diverse portfolio, which includes medicines, medical devices, food supplements and cosmetics, through four brands, in the rheumatology, well-being, dermo-cosmetics, wound healing and fertility therapeutic areas. Promogen distributes its products to over 9,000 pharmacies and drugstores in France, through an in-house sales force of approximately 40 representatives.
Oaklins’ team in France acted as advisor to the shareholders of Laboratoire Tilman in this transaction.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more